4.6 Article

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer

Journal

FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.740427

Keywords

breast cancer; tumor mutational burden; tumor-infiltrating lymphocytes (TILs); neoadjuvant chemotherapies (NACs); T-cell receptors (TCRs)

Categories

Funding

  1. Guangzhou Health ST Project [20191A011097]
  2. Guangzhou ST Project [202102080096, 201904010331]
  3. Guangdong Educational Bureau Program [2020KTSCX105]
  4. Guangdong Provincial Natural Science Program [2019A1515010900, DFJH201903, KJ012019444, 8197103306]
  5. Natural Science Foundation of Guangdong Province [2017A030313551]
  6. Natural Science Foundation China [82173202]
  7. NSFC [82072899]
  8. Guangzhou Municipal Science and Technology Bureau [202102010042]
  9. Guangzhou High-level Clinical Key Specialty Construction Project and Clinical Key Specialty Project of Guangzhou Medical University [202005]

Ask authors/readers for more resources

Immune characteristics, TMB, TCR, and TILs were simultaneously analyzed in breast cancer patients receiving neoadjuvant chemotherapy. Higher TMB and TCR diversity index were found in non-pCR patients compared to pCR patients, with a linear correlation between TMB and TCR. High TCR clonality and CD8+ expression were associated with disease-free survival, suggesting potential for guiding neo-adjuvant treatment in operable breast cancers.
Immune characteristics were reported correlated to benefit neoadjuvant chemotherapy (NAC) in breast cancer, yet integration of comprehensive genomic alterations and T-cell receptors (TCR) to predict efficacy of NAC needs further investigation. This study simultaneously analyzed TMB (Tumor Mutation Burden), TCRs, and TILs (tumor infiltrating lymphocyte) in breast cancers receiving NAC was conducted in a prospective cohort (n = 22). The next-generation sequencing technology-based analysis of genomic alterations and TCR repertoire in paired breast cancer samples before and after NAC was conducted in a prospective cohort (n = 22). Fluorescent multiplex immunohistochemistry was used to stain CD4, CD8, PD1, TIM3, and cytokeratins simultaneously in those paired samples. TMB in pretreatment tumor tissues and TCR diversity index are higher in non-pCR patients than in pCR patients (10.6 vs. 2.3; p = 0.043) (2.066 vs. 0.467; p = 0.010). TMB and TCR diversity index had linear correlation (y = 5.587x - 0.881; r = 0.522, p = 0.012). Moreover, infiltrating T cells are significantly at higher presence in pCR versus non-pCR patients. Dynamically, the TMB reduced significantly after therapy in non-pCR patients (p = 0.010) but without TCR index change. The CDR3 peptide AWRSAGNYNEQF is the most highly expressed in pre-NAC samples of pCR patients and in post-NAC samples of non-pCR patients. In addition to pCR, high clonality of TCR and high level of CD8(+) expression are associated with disease-free survival (DFS). TCR index and TMB have significant interaction and may guide neo-adjuvant treatment in operable breast cancers. Response to NAC in tumors with high TCR clonality may be attributable to high infiltration and expansion of tumor-specific CD8 positive effector cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available